is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting, following its promising survival ...

is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology's ("ESMO”) Breast Cancer meeting, following its promising survival ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically ...

The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...

Researchers evaluated outcomes and safety of both the pivotal and confirmatory trials. They used ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) to score both sets of trials, as well.

In a proud moment for the nation, Bangladesh has been selected to host a local session of the ESMO Examination 2025, a globally recognised assessment conducted by the European Society for Medical ...

It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 ...

At close: April 30 at 5:35:42 PM GMT+2 ...

At close: 25 April at 16:00:02 GMT-4 ...

At close: April 24 at 5:43:38 p.m. GMT+2 ...